I want to get continuous structured data on emerging prescription drug formularies, reimbursement changes, and clinical trial results from competitor insurance provider websites, regulatory databases, and pharmaceutical news outlets.
A shared demo template. Read-only preview of what would be monitored in a real pilot.
Click to explore each section
This is a real demo!
Click to explore each section.
Pilot Configuration
Goal
I want to get continuous structured data on emergi...
Access real-time insights on drug formularies and reimbursement trends — automated intelligence without the manual effort
12 website or app sources
The Jsonify AI will open these automatically to explore and find your information
9
data columns
12
dashboard widgets
3
integrations
1
notification
Recommended
Pilot Phase (Scoped Evaluation)
Up to 12 weeks
€3,000
/ month
Typical scope: multi-country, weekly updates, multiple categories
- Real data from real sources
- Live dashboards or export feeds
- Validate scope, refresh cadence, quality
- Fixed price, no ongoing commitment
Most teams start here to validate fit before expanding.
Now, schedule a short call below to confirm scope and start the pilot, or build something new.
or email us at paul@jsonify.co
Data sources are the websites and apps where information will be collected from. These can be changed or expanded at any time. This is turned into data rows.
Sample data preview. This is synthetic test data generated to illustrate the structure. Real data from your sources will be populated during the pilot. This data powers the dashboard widgets.
| id | Source | Provider | Formulary | Drug | Reimbursement | Coverage Effective | Last Updated | Status | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
|
BlueCross BlueShield of MA | MA Preferred Rx Tier 3 | tirzepatide (Zepbound) 5 mg | $850.00 per 30-day supply (prior auth required) | Feb 1, 2026 | Feb 3, 2026 | Prior Authorization | ||
| 2 |
|
UnitedHealthcare | UHC National Rx List 2026 | aducanumab (Aduhelm) 100 mg | Medicare Part B reimbursement referenced; patient coinsurance varies | Jan 30, 2026 | Feb 2, 2026 | Limited Coverage - CMS Guidance | ||
| 3 |
|
Cigna | Cigna Specialty Preferred 2026 | lecanemab (Leqembi) 10 mg/mL | $1,200.00 infusion admin fee + drug billed under medical benefit | Feb 1, 2026 | Feb 4, 2026 | Medical Benefit | ||
| 4 |
|
Humana | Humana Commercial Rx 2026 | oral semaglutide (Rybelsus) 14 mg | $420.00 per 30-day; mail-order discount $380.00 | Feb 2, 2026 | Feb 4, 2026 | Preferred | ||
| 5 |
|
Aetna | Aetna Open Choice 2026 | amivantamab (Rybrevant) 350 mg | $9,500.00 per cycle (case-by-case review) | Jan 29, 2026 | Feb 3, 2026 | Case-by-Case Review | ||
| 6 |
|
Kaiser Permanente | KP Permanente Formularies 2026 | inclisiran (Leqvio) 284 mg | $600.00 per dose (q6 months) | Feb 1, 2026 | Feb 3, 2026 | Preferred Specialty | ||
| 7 |
|
Anthem | Anthem Blue Cross Rx 2026 | olaparib (Lynparza) 150 mg | $3,200.00 per 30-day (oncology carve-out) | Feb 2, 2026 | Feb 4, 2026 | Specialty Coverage | ||
| 8 |
|
WellCare | WellCare Medicare Rx 2026 | sotagliflozin (Zynquista) 200 mg | $0.00 copay for select tier members; otherwise $45.00 | Feb 1, 2026 | Feb 3, 2026 | Preferred Tier 1 | ||
| 9 |
|
Centene | Centene Medicaid Rx 2026 | voretigene neparvovec (Luxturna) 1 dose | Single-dose payment negotiated: $480,000.00 (outcomes-based contract) | Jan 31, 2026 | Feb 2, 2026 | Restricted - Outcomes Contract | ||
| 10 |
|
CareFirst | CareFirst Commercial Rx 2026 | teplizumab-mzwv (Tzield) 14-day course | $8,400.00 per course; step therapy applies | Feb 3, 2026 | Feb 4, 2026 | Step Therapy | ||
| 11 |
|
State Farm Health | State Farm Rx Select 2026 | pirtobrutinib 100 mg | $6,750.00 per 30-day (prior auth required) | Feb 2, 2026 | Feb 4, 2026 | Prior Authorization | ||
| 12 |
|
BCBS of NJ | NJ Commercial Specialty 2026 | donanemab 700 mg | $16,500.00 per infusion course; limited network sites | Feb 1, 2026 | Feb 3, 2026 | Limited Network | ||
| 13 |
|
Highmark | Highmark Medicare Rx 2026 | evinacumab (Evkeeza) 15 mg/kg | $25,000.00 per infusion (medical benefit) | Feb 1, 2026 | Feb 3, 2026 | Medical Benefit - Prior Auth | ||
| 14 |
|
Molina Healthcare | Molina Medicaid Rx 2026 | risankizumab (Skyrizi) 150 mg | $1,100.00 per 90-day injection; PA for biologics | Feb 2, 2026 | Feb 4, 2026 | Prior Authorization | ||
| 15 |
|
Harvard Pilgrim | HPHC Commercial Rx 2026 | mounjaro (tirzepatide) 15 mg | $960.00 per 30-day; step edit from GLP-1 naïve | Feb 3, 2026 | Feb 4, 2026 | Step Edit | ||
| 16 |
|
Oscar Health | Oscar Marketplace Rx 2026 | nadofaragene firadenovec 1 dose | $9,750.00 per instillation (urology outpatient setting) | Jan 31, 2026 | Feb 2, 2026 | Specialty Procedure | ||
| 17 |
|
GuideWell (Florida Blue) | Florida Blue Rx 2026 | tepotinib 450 mg | $7,200.00 per 30-day (oncology prior auth) | Feb 2, 2026 | Feb 4, 2026 | Oncology Prior Auth | ||
| 18 |
|
EmblemHealth | EmblemHealth Commercial Rx 2026 | ubrogepant 50 mg | $120.00 per 30-day (retail) | Feb 3, 2026 | Feb 4, 2026 | Preferred | ||
| 19 |
|
Capital BlueCross | Capital Rx Advantage 2026 | pegunigalsidase alfa 1 mg/kg | $65,000.00 per infusion; medical policy requires genetic confirmation | Feb 1, 2026 | Feb 3, 2026 | Restricted - Genetic Confirmation | ||
| 20 |
|
Independence Blue Cross | IBC Commercial Formularies 2026 | casirivimab/imdevimab (REGEN-COV) 1 dose | Covered under EUA guidance; variable reimbursement by site | Feb 2, 2026 | Feb 4, 2026 | EUA Guidance | ||
| 21 |
|
Devoted Health | Devoted Medicare Rx 2026 | bimagrumab 100 mg | $4,200.00 per infusion (investigational coverage policy) | Feb 1, 2026 | Feb 3, 2026 | Investigational Coverage | ||
| 22 |
|
BlueCross BlueShield of IL | BCBS IL Specialty 2026 | aclidinium bromide 400 mcg | $85.00 per 30-day (preferred inhaler) | Feb 3, 2026 | Feb 4, 2026 | Preferred | ||
| 23 |
|
Premera Blue Cross | Premera Rx Standard 2026 | tebentafusp (Kimmtrak) 20 mcg | $110,000.00 per course; limited to melanoma centers | Feb 1, 2026 | Feb 3, 2026 | Center of Excellence Only | ||
| 24 |
|
BlueShield of CA | Anthem Blue Shield Rx 2026 | vutrisiran (Amvuttra) 25 mg | $1,050.00 per 30-day; specialty pharmacy distribution | Feb 2, 2026 | Feb 4, 2026 | Specialty Pharmacy | ||
| 25 |
|
Geisinger Health Plan | Geisinger Rx 2026 | niraparib 300 mg | $2,900.00 per 30-day with oncology prior auth | Feb 1, 2026 | Feb 3, 2026 | Oncology Prior Auth | ||
| 26 |
|
Tricare | TRICARE National Formulary 2026 | molnupiravir 800 mg | Covered under antiviral policy; $0 copay for active duty dependents | Feb 3, 2026 | Feb 4, 2026 | Covered - Limited Indication | ||
| 27 |
|
Regence | Regence Commercial Rx 2026 | sutimlimab 60 mg/mL | $14,500.00 per infusion; utilization management applies | Feb 2, 2026 | Feb 4, 2026 | Utilization Management | ||
| 28 |
|
MVP Health Care | MVP Rx Select 2026 | fexinidazole 100 mg | $1,200.00 per treatment course (rare disease policy) | Feb 1, 2026 | Feb 3, 2026 | Rare Disease Coverage | ||
| 29 |
|
Oscar Health NY | Oscar NY Marketplace Rx 2026 | ubrogepant 25 mg | $95.00 per 30-day; quantity limits apply | Feb 3, 2026 | Feb 4, 2026 | Quantity Limit | ||
| 30 |
|
Harvard Pilgrim Health Care | HPHC Medicare Rx 2026 | zasurlimab 150 mg | $2,400.00 per dose (awaiting final LCD) | Feb 2, 2026 | Feb 4, 2026 | Pending LCD | ||
| Looking for more? Great news − this is just a small sample. Jsonify production workflows process anywhere from tens of thousands to millions of real data rows per run! | ||||||||||
From
–
To
Filters
Loading filters...
Loading filters...
Total Formularies Monitored
450
total formularies monitored
8%
Top Competitor Formularies
Volume of New Drug Approvals
Total Clinical Trials Recorded
4,567
total clinical trials recorded
8%
Most Common Drug Class Changes
Key Observations on Market Changes
Recent changes in reimbursement policies observed from competitor insurance providers could impact market dynamics significantly.
Emerging therapies from the latest clinical trials show a trend towards biologics, reflecting a shift in treatment paradigms.
Monitoring updates from sources like cms.gov and fda.gov will be crucial in anticipating shifts in drug formularies.
Reimbursement Changes by Type
Recent Clinical Trial Results
| Source | Drug Name | Phase | Results Summary | Date |
|---|---|---|---|---|
|
|
Drug A | Phase 3 | Successfully met primary endpoint with significant improvement in patient outcomes. | 2026-01-15 |
|
|
Drug B | Phase 2 | No serious adverse events reported; continuing to Phase 3. | 2026-01-20 |
|
|
Drug C | Phase 1 | Showed promising results in safety and dosage levels. | 2026-01-25 |
|
|
Drug D | Phase 3 | Demonstrated efficacy in a large population; awaiting further analysis. | 2026-01-28 |
|
|
Drug E | Phase 2 | Mixed results; further investigation needed for efficacy. | 2026-01-30 |
|
|
Drug F | Phase 1 | Initial trials show good tolerance among participants. | 2026-01-31 |
Sources of Drug Information
Emerging Drug Trends Over Time
Latest Reimbursement Changes
| Date | Source | Product | Reimbursement Change | Notes |
|---|---|---|---|---|
| 2026-01-15 |
|
Drug A | Increased by 15% | Expanded coverage |
| 2026-01-20 |
|
Drug B | Decreased by 10% | New evidence of side effects |
| 2026-01-25 |
|
Drug C | No Change | Approval pending |
| 2026-01-28 |
|
Drug D | Increased by 20% | New indications approved |
| 2026-02-01 |
|
Drug E | Decreased by 5% | Cost-cutting measures |
| 2026-02-02 |
|
Drug F | Increased by 12% | Market response positive |
Reimbursement Change Trends
Structured data feeds are included — we're happy to help with API integration and automation.
JSON
Loading...
CSV
Loading...
Looking for more? Great news − this is just a small sample. Typically, our commercial customers process tens of thousands to millions of data points per task!
Radar continuously monitors your selected web sources and alerts you the moment something changes.
+7
Recent change
New Listing Appears
3h ago
Emerging Drug Formulary new formulary detected
Recent change
Reimbursement Change Detected
2m ago
Drug XYZ reimbursement rate updated
Recent change
Availability Change
5m ago
Clinical Trial ABC is now enrolling participants
Recent change
Coverage Gap Identified
12m ago
Drug Coverage missing from insurance plans
Recent change
Clinical Trial Results Updated
5m ago
Trial for Drug ABC new results published
Data connections determine where the collected data will be delivered. You can add, remove, or change connections at any time.
Scroll down to see more